ICU vs. FEMY, MODD, RVP, NMTC, LNSR, DRIO, CODX, LUCD, IINN, and NEPH
Should you be buying SeaStar Medical stock or one of its competitors? The main competitors of SeaStar Medical include Femasys (FEMY), Modular Medical (MODD), Retractable Technologies (RVP), NeuroOne Medical Technologies (NMTC), LENSAR (LNSR), DarioHealth (DRIO), Co-Diagnostics (CODX), Lucid Diagnostics (LUCD), Inspira Technologies Oxy B.H.N. (IINN), and Nephros (NEPH). These companies are all part of the "surgical & medical instruments" industry.
SeaStar Medical (NASDAQ:ICU) and Femasys (NASDAQ:FEMY) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their community ranking, risk, institutional ownership, dividends, analyst recommendations, valuation, media sentiment, profitability and earnings.
SeaStar Medical currently has a consensus target price of $5.00, indicating a potential upside of 825.93%. Femasys has a consensus target price of $11.33, indicating a potential upside of 765.14%. Given SeaStar Medical's higher probable upside, analysts plainly believe SeaStar Medical is more favorable than Femasys.
In the previous week, SeaStar Medical had 2 more articles in the media than Femasys. MarketBeat recorded 5 mentions for SeaStar Medical and 3 mentions for Femasys. SeaStar Medical's average media sentiment score of 0.60 beat Femasys' score of 0.55 indicating that SeaStar Medical is being referred to more favorably in the media.
Femasys received 20 more outperform votes than SeaStar Medical when rated by MarketBeat users. However, 100.00% of users gave SeaStar Medical an outperform vote while only 63.64% of users gave Femasys an outperform vote.
1.7% of SeaStar Medical shares are held by institutional investors. Comparatively, 65.3% of Femasys shares are held by institutional investors. 4.5% of SeaStar Medical shares are held by company insiders. Comparatively, 16.4% of Femasys shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
SeaStar Medical has a beta of -1.18, meaning that its share price is 218% less volatile than the S&P 500. Comparatively, Femasys has a beta of -3, meaning that its share price is 400% less volatile than the S&P 500.
SeaStar Medical has a net margin of 0.00% compared to Femasys' net margin of -1,329.10%. SeaStar Medical's return on equity of 0.00% beat Femasys' return on equity.
Femasys has higher revenue and earnings than SeaStar Medical. Femasys is trading at a lower price-to-earnings ratio than SeaStar Medical, indicating that it is currently the more affordable of the two stocks.
Summary
SeaStar Medical and Femasys tied by winning 8 of the 16 factors compared between the two stocks.
Get SeaStar Medical News Delivered to You Automatically
Sign up to receive the latest news and ratings for ICU and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ICU and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
SeaStar Medical Competitors List
Related Companies and Tools
